SarcoMedUSA was formed in Texas in 2017 to determine if Pulmozyme could improve Pulmonary Sarcoidosis.
The company is nearing a nal license agreement for Tigerase. Tigerase is approved and SarcoMedUSA will
conduct a sponsored Pulmonary Sarcoidosis study in a tertiary referral University that specializes in Sarcoidosis treatment.

Additionally, the company has an option on a no-alpha IL-2 mutein for cancer. SarcoMedUSA is working with Roswell Park Cancer Center in New York. There are nal toxicology studies being completed in humanized mice studies which are ongoing and in our lab. The drug has been used in the Cuban clinic whereby two (2) of twelve (12) patients with advanced cancer had partial remission.

SarcoMed has assembled a nationally recognized team of drug development experts to move SM001 (alidornase) into the clinic. In 2021, our team was able to successfully complete a Pre-IND meeting with the Pulmonary Division of the FDA, which granted us orphan status.

Pulmonary Sarcoidosis is a signicant market opportunity, with potential to generate over a billion dollars in annual revenue and help address a signicant unmet need for the world wide patient population. SarcoMed is also exploring additional indications for SM001 such as Adult Respiratory Distress Syndrome, Idiopathic
Pulmonary Fibrosis and Cystic Fibrosis.